142 related articles for article (PubMed ID: 21975335)
1. Prognostic significance of biochemical markers in African Burkitt's lymphoma.
Arthur FK; Owusu L; Yeboah FA; Rettig T; Osei-Akoto A
Clin Transl Oncol; 2011 Oct; 13(10):731-6. PubMed ID: 21975335
[TBL] [Abstract][Full Text] [Related]
2. Rescue chemotherapy for patients with resistant or relapsed endemic Burkitt's lymphoma.
Hesseling PB; Molyneux E; Kamiza S; Broadhead R
Trans R Soc Trop Med Hyg; 2008 Jun; 102(6):602-7. PubMed ID: 18417177
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
[TBL] [Abstract][Full Text] [Related]
5. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
Mead GM; Sydes MR; Walewski J; Grigg A; Hatton CS; Pescosta N; Guarnaccia C; Lewis MS; McKendrick J; Stenning SP; Wright D;
Ann Oncol; 2002 Aug; 13(8):1264-74. PubMed ID: 12181251
[TBL] [Abstract][Full Text] [Related]
6. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
Ribrag V; Koscielny S; Bosq J; Leguay T; Casasnovas O; Fornecker LM; Recher C; Ghesquieres H; Morschhauser F; Girault S; Le Gouill S; Ojeda-Uribe M; Mariette C; Cornillon J; Cartron G; Verge V; Chassagne-Clément C; Dombret H; Coiffier B; Lamy T; Tilly H; Salles G
Lancet; 2016 Jun; 387(10036):2402-11. PubMed ID: 27080498
[TBL] [Abstract][Full Text] [Related]
7. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types).
Bernstein JI; Coleman CN; Strickler JG; Dorfman RF; Rosenberg SA
J Clin Oncol; 1986 Jun; 4(6):847-58. PubMed ID: 3711961
[TBL] [Abstract][Full Text] [Related]
8. Survival of children with endemic Burkitt lymphoma in a prospective clinical care project in Uganda.
McGoldrick SM; Mutyaba I; Adams SV; Larsen A; Krantz EM; Namirembe C; Mooka P; Nabakooza S; Ndagire M; Mubiru K; Nabwana M; Nankinga R; Gerdts S; Gordon-Maclean C; Geriga F; Omoding A; Sessle E; Kambugu J; Uldrick TS; Orem J; Casper C
Pediatr Blood Cancer; 2019 Sep; 66(9):e27813. PubMed ID: 31157502
[TBL] [Abstract][Full Text] [Related]
9. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
10. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia.
Schwenn MR; Blattner SR; Lynch E; Weinstein HJ
J Clin Oncol; 1991 Jan; 9(1):133-8. PubMed ID: 1985162
[TBL] [Abstract][Full Text] [Related]
11. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
Spreafico F; Massimino M; Luksch R; Casanova M; Cefalo GS; Collini P; Ferrari A; Polastri D; Terenziani M; Gasparini M; Fossati-Bellani F
J Clin Oncol; 2002 Jun; 20(12):2783-8. PubMed ID: 12065554
[TBL] [Abstract][Full Text] [Related]
12. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults.
Magrath IT; Janus C; Edwards BK; Spiegel R; Jaffe ES; Berard CW; Miliauskas J; Morris K; Barnwell R
Blood; 1984 May; 63(5):1102-11. PubMed ID: 6546890
[TBL] [Abstract][Full Text] [Related]
13. [Maxillofacial location of Burkitt's lymphoma in children treated at the University Hospital Center in Bamako, Mali: a 24-case series].
Togo B; Keita M; Medefo D; Traore F; Sidibe T
Med Trop (Mars); 2008 Dec; 68(6):600-2. PubMed ID: 19639827
[TBL] [Abstract][Full Text] [Related]
14. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
15. Skin involvement in Burkitt's lymphoma.
Thakkar D; Lipi L; Misra R; Yadav SP
Hematol Oncol Stem Cell Ther; 2018 Dec; 11(4):251-252. PubMed ID: 29397332
[TBL] [Abstract][Full Text] [Related]
16. Determinants of survival in Nigerians with Burkitt's lymphoma.
Kagu MB; Durosinmi ; Adeodu OO; Akinola NO; Adediran IA; Salawu L
Afr J Med Med Sci; 2004 Sep; 33(3):195-200. PubMed ID: 15819463
[TBL] [Abstract][Full Text] [Related]
17. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
Montoto S; Wilson J; Shaw K; Heath M; Wilson A; McNamara C; Orkin C; Nelson M; Johnson M; Bower M; Cwynarski K
AIDS; 2010 Mar; 24(6):851-6. PubMed ID: 20124971
[TBL] [Abstract][Full Text] [Related]
18. Curability of advanced Burkitt's lymphoma in children by intensive short-term chemotherapy.
Gasparini M; Rottoli L; Massimino M; Gianni MC; Ballerini E; Ravagnani F; Pupa S; Fossati-Bellani F
Eur J Cancer; 1993; 29A(5):692-8. PubMed ID: 8471326
[TBL] [Abstract][Full Text] [Related]
19. Outcome is unchanged by adding vincristine upfront to the Malawi 28-day protocol for endemic Burkitt lymphoma.
Depani S; Banda K; Bailey S; Israels T; Chagaluka G; Molyneux E
Pediatr Blood Cancer; 2015 Nov; 62(11):1929-34. PubMed ID: 26052841
[TBL] [Abstract][Full Text] [Related]
20. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine.
Murphy SB; Bowman WP; Abromowitch M; Mirro J; Ochs J; Rivera G; Pui CH; Fairclough D; Berard CW
J Clin Oncol; 1986 Dec; 4(12):1732-9. PubMed ID: 3491184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
